Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement t

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overwe

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary o

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overwe

BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains

Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and low

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.69) per share which beat the anal

Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targe

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raise

Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to

Item 7.01    Regulation FD Disclosure. Royalty Agreement Closing and Funding On March 27, 2026, the

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overwe

Goldman Sachs analyst Salveen Richter maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and

Stifel analyst Paul Mattels maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the

Wall Street analysts change ratings on top stocks: BNP Paribas cuts Chewy Inc, Bernstein cuts Qualco

Denali Therapeutic snags FDA accelerated approval for Avlayah for Hunter syndrome, analyst flags str

Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raise

HC Wainwright & Co. analyst Andrew S. Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a

https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestation

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

BTIG analyst Thomas Shrader maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.73) per share which beat the anal

Wolfe Research analyst Rudy Li initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Pee

REGENXBIO shares fall after the FDA issues a response letter on its Hunter syndrome gene therapy, ra

BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinf

Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 d

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilizat

Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and low

Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that it intends to offer and sell $200 millio

FDA placed hold on Denali's drug for Pompe disease, requesting changes to protocol. No additiona

Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and rai

BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains

Denali Therapeutics Inc. (NASDAQ:DNLI) and Royalty Pharma plc (NASDAQ:RPRX) today announced a $275 m

JP Morgan analyst Jessica Fye maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and r

FDA extends review of Denali Therapeutics' tividenofusp alfa for Hunter syndrome to April 2026;

Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that the U.S. Food and Drug Administration (F

Cantor Fitzgerald analyst Josh Schimmer reiterates Denali Therapeutics (NASDAQ:DNLI) from Overwei

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overwe

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.72) per share which missed the an

FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approvalTividen

B of A Securities analyst Tazeen Ahmad maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and

https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzh

Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lower